- Home
- KAVL vs KZIA Comparison
KAVL vs KZIA Comparison
Compare KAVL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- KZIA
- Stock Information
- Founded
- KAVL 1998
- KZIA 1994
- Country
- KAVL United States
- KZIA Australia
- Employees
- KAVL N/A
- KZIA N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- KZIA Health Care
- Exchange
- KAVL Nasdaq
- KZIA Nasdaq
- Market Cap
- KAVL 11.5M
- KZIA 6.0M
- IPO Year
- KAVL N/A
- KZIA 1999
- Fundamental
- Price
- KAVL $1.29
- KZIA $0.98
- Analyst Decision
- KAVL
- KZIA Strong Buy
- Analyst Count
- KAVL 0
- KZIA 2
- Target Price
- KAVL N/A
- KZIA $11.50
- AVG Volume (30 Days)
- KAVL 370.5K
- KZIA 5.5M
- Earning Date
- KAVL 02-10-2025
- KZIA 03-26-2025
- Dividend Yield
- KAVL N/A
- KZIA N/A
- EPS Growth
- KAVL N/A
- KZIA N/A
- EPS
- KAVL N/A
- KZIA N/A
- Revenue
- KAVL $6,886,665.00
- KZIA $1,655,324.00
- Revenue This Year
- KAVL $652.90
- KZIA $806.89
- Revenue Next Year
- KAVL N/A
- KZIA N/A
- P/E Ratio
- KAVL N/A
- KZIA N/A
- Revenue Growth
- KAVL N/A
- KZIA 248000.00
- 52 Week Low
- KAVL $0.58
- KZIA $0.91
- 52 Week High
- KAVL $9.69
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- KAVL 54.26
- KZIA 30.47
- Support Level
- KAVL $1.29
- KZIA $1.31
- Resistance Level
- KAVL $1.49
- KZIA $1.60
- Average True Range (ATR)
- KAVL 0.17
- KZIA 0.27
- MACD
- KAVL -0.01
- KZIA 0.02
- Stochastic Oscillator
- KAVL 66.02
- KZIA 4.11
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.